A Cumberland drug company has raised $3 million in funding as it works toward gaining approval for a new cannabis-derived treatment for lung diseases.
RS BioTherapeutics plans to use the capital from its second seed round to focus on developing a medication for chronic obstructive pulmonary disease, or COPD. Co-founder and Chief Strategy Officer Justin Molignoni said the company will apply for an investigational new drug application from the U.S. Food and Drug Administration and hopes to submit…
